Cynata Therapeutics Limited (AU:CYP) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cynata Therapeutics Limited, an Australian biotech firm, is set to present its innovative cell therapy for diabetic foot ulcers at the prestigious ISCT ANZ 2024 Regional Meeting in New Zealand. The company’s CEO, Dr. Kilian Kelly, will showcase the Cymerus™ iPSC-derived MSC topical wound dressing product candidate, CYP-006TK, highlighting its clinical development milestones. Cynata’s participation underscores its role in advancing cell therapeutics and its commitment to delivering novel treatments for various diseases including GvHD, osteoarthritis, and diabetic foot ulcers.
For further insights into AU:CYP stock, check out TipRanks’ Stock Analysis page.